The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Britain says it expects its vaccine contracts to be met

Fri, 29th Jan 2021 08:23

* UK refuses to publish Astra supply details

* Scotland says it will publish vaccine supply data

* EU warns drug companies over supply delays
(Adds UK PM Johnson's spokesman, Scottish health minister)

By Sarah Young and William James

LONDON, Jan 29 (Reuters) - Britain is confident it will
receive sufficient COVID-19 vaccine doses to keep its programme
on track despite a dispute between the European Union and
drugmaker AstraZeneca, Prime Minister Boris Johnson's spokesman
said on Friday.

EU Commission Head Ursula von der Leyen has demanded that
Astrazeneca deliver contracted vaccine supplies from Britain to
EU states, and has dimissed the notion that the United Kingdom
should have first rights to doses produced there.

The EU has warned drug companies that it would use all legal
means or even block exports unless they agreed to deliver shots
as promised.

The bloc published its contract with AstraZeneca on Friday,
which said the Anglo-Swedish drugmaker should use facilities in
Britain as well as continental Europe in its best efforts to
manufacture its vaccines for the EU.

Prime Minister Boris Johnson's spokesman said on Friday the
government would not discuss contractual matters. But he said
the government expected contracts to be "facilitated" and he was
confident of its supply.

"AstraZeneca has clearly stated they will be able to provide
2 million vaccine doses a week and we've said we will get that
to people as quickly as possible," he said.

While Britain is running ahead of its European peers on
vaccinations, with almost 7.5 million receiving their first dose
so far, the British COVID-19 death toll has surpassed 100,000,
and is the highest in Europe.

A third national lockdown in England is expected to run
until at least March as ministers try to bring a more contagious
variant of the virus under control. Scotland, Wales and Northern
Ireland, whose governments decide on their own measures, are
also living under tight restrictions.

AHEAD ON MANUFACTURING

The swiftest mass vaccination drive in history is stoking
tensions across the world as big powers buy up doses in bulk and
poorer nations try to navigate a financial and diplomatic
minefield to collect whatever supplies are left.

The United Kingdom has secured 367 million doses of the
seven most promising vaccines, including 100 million doses of
the AstraZeneca vaccine which was developed by Oxford
University.

Among those procured by Britain include a vaccine developed
by Novavax, which on Thursday said it proved 89%
effective in a UK trial, and Johnson & Johnson, which on Friday
said its shot was between 72% to 66% effective.

Kate Bingham, the former head of Britain's vaccine
taskforce, said the country had been able to secure supplies by
supporting pharmaceutical companies, setting up clinical trials
quickly and helping firms procure equipment to increase
manufacturing.

She declined to comment on the detail of the contract with
AstraZeneca but said the United Kingdom had benefited from early
work to be ready to make vaccines.

"That is ultimately the difference as to why we're so far
ahead on manufacturing," Bingham said, adding that she did not
expect the EU to block vaccine exports to the United Kingdom.

NO LONGER TENABLE

Scotland will publish COVID-19 detailed vaccine supply data
next week even though the British government has refused to do
so.

British prisons minister Lucy Frazer said the government
could not publish supply details for national security reasons,
which she declined to specify.

Scotland's health minister Jeane Freeman said that citing
national security was "not credible" because the British
government had repeatedly briefed statistics to reporters
showing how much vaccine Scotland had been allocated.

"We've held off publication in the past at their request.
But that's no longer tenable," she said at a news conference.

"The public have a right to clarity and we will give them
that. We're not talking about future supplies, we're talking
about known supplies."
(Reporting by Sarah Young, Alistair Smout and William James;
editing by Angus MacSwan)

More News
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.